



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE,
NET-A-METERED, BOWLING STREET,
AND WHITE ROAD, WORLI
MUMBAI - 400 020.

TELEPHONE : 2202 1111, 2202 1112, 2202 1113
FAX : 2202 1114, 2202 1115
E-MAIL : info@jbchempharm.com
WEBSITE : www.jbchempharm.com
CIN : L24202MH1997PLC000001

StockExchange-NSE letters/MM:SA:594

February 3, 2016

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E) Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Outcome of the Meeting of the board of directors - Unaudited Financial Results for the quarter ended on December 31, 2015.


In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on December 31, 2015 accompanied by limited review report. These financial results have been approved and taken on record by the board of directors at its meeting held today, which commenced at 12.00 noon and concluded at 1.45 p.m.

We request you to take the above on record.


Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta
Company Secretary and Vice President - Compliance

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE.

NEELAM CENTRE, BOWING 1TH FLR

HIND CYCLE ROAD, WORLI

MUMBAI - 400 010

PHONE : 022-2493 0242 - 2493 0918

FAX : 022-2493 0004 - 2493 9638

E-MAIL : info@jbdpl.com

Website : www.jbdpl.com

CIN : L21390MH1976PLC019380

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2015

Sl.No.	Particulars	Quarter ended			Nine Months ended		(Rs. in lakhs) Previous Year ended
		31-12-2015	30-09-2015	31-12-2014	31-12-2015	31-12-2014	31-03-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	27,058.46	28,070.95	25,680.59	83,044.34	78,837.90	1,03,813.61
	b. Other Operating Income	776.95	607.15	666.25	1,890.02	1,794.99	2,328.51
	Total Income from Operations (Net) (a+b)	27,835.41	28,678.10	26,346.84	84,934.36	80,632.89	1,06,142.12
2	Expenses						
	a. Cost of materials consumed	9,497.53	9,819.75	8,411.04	28,340.26	25,453.51	34,158.73
	b. Purchases of stock-in-trade	1,073.13	2,003.69	1,629.84	5,385.92	7,102.75	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(395.41)	(189.50)	278.90	14.63	208.96	(68.24)
	d. Employee benefits expense	3,910.55	4,033.19	3,551.38	12,040.75	10,822.88	14,681.81
	e. Depreciation and amortization expense	1,022.56	1,004.00	1,011.00	3,003.56	3,002.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	66.70	86.78	41.70	272.20	18.22	58.16
	g. Other Expenses	7,222.56	7,556.39	7,578.87	22,099.58	21,579.68	28,633.60
	Total Expenses	22,397.62	24,314.30	22,502.73	71,156.90	68,188.00	90,233.71
3	Profit from Operations before Other Income and Finance Cost (1-2)	5,437.79	4,363.80	3,844.11	13,777.46	12,444.89	15,908.41
4	Other Income	1,290.99	2,651.63	195.92	4,372.33	890.40	1,040.88
5	Profit from ordinary activities before Finance Cost (3+4)	6,728.78	7,015.43	4,040.03	18,149.79	13,335.29	16,949.29
6	Finance Cost	259.83	308.41	284.71	739.27	642.68	665.01
7	Profit from ordinary activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,468.95	6,707.02	3,755.32	17,410.52	12,692.61	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	35.27	(478.49)	(241.28)	(44.58)	(654.80)	(373.86)
9	Profit from ordinary activities before Tax (7+8)	6,504.22	6,228.53	3,514.04	17,365.94	12,037.81	15,910.42
10	Tax expense	1,515.00	1,330.00	1,097.26	4,050.00	3,253.20	4,552.17
11	Net Profit from ordinary activities after Tax (9-10)	4,989.22	4,898.53	2,416.78	13,315.94	8,784.61	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.40	1,696.16	1,696.40	1,696.16	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,934.99
14	Earnings per share (EPS) (of Rs. 2/- each) (not annualised)						
	(1) Basic	5.88	5.78	2.85	15.70	10.36	13.40
	(2) Diluted	5.88	5.78	2.85	15.70	10.36	13.39
	See accompanying notes to the Financial Results						

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on February 3, 2016.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on December 31, 2015.
- The other income includes Rs. 12.57 crores on account of profit / dividend on investments.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been re-grouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
J.B. Mody
Chairman & Managing Director

Place : Mumbai

Date : February 3, 2016

INDEPENDENT AUDITOR'S REVIEW REPORT


To
The Board of Directors of
J. B. CHEMICALS & PHARMACEUTICALS LIMITED

We have reviewed the accompanying Statement of Unaudited Financial Results of J. B. CHEMICALS & PHARMACEUTICALS LIMITED ('the Company'), for period ended 31st December, 2015 ('the Statement'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J. K. Shah & Co.
Chartered Accountants
Firm Regn. No. 109606W


J.K. Shah
Partner
Membership No. 03662



Place: Mumbai
Date: 03rd February, 2016



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
'NEELAM CENTRE', B WING, 4TH FLOOR
HIND CYCLE ROAD, WORLI
MUMBAI - 400 030

PHONE: 022-2482 2223 2493 0918
FAX: 022-2493 0534 2493 9633
E-MAIL: info@jbcpl.com
Website: www.jbcpl.com
CIN: L24390MH1976PLC019380


STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2015

Sl.No.	Particulars	Quarter ended			Nine Months ended		Previous Year ended
		31-12-2015	30-09-2015	31-12-2014	31-12-2015	31-12-2014	31-03-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations						
	a. Net sales (Net of excise duty)	27,058.46	28,070.95	25,680.59	83,044.34	78,837.90	1,03,813.61
	b. Other Operating Income	776.95	607.15	666.25	1,890.02	1,794.99	2,328.51
	Total Income from Operations (Net) (a+b)	27,835.41	28,678.10	26,346.84	84,934.36	80,632.89	1,06,142.12
2	Expenses						
	a. Cost of materials consumed	9,497.53	9,819.75	8,411.04	28,340.26	25,453.51	34,158.73
	b. Purchases of stock-in-trade	1,073.13	2,003.69	1,629.84	5,385.92	7,102.75	9,009.66
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(395.41)	(189.50)	278.90	14.63	208.96	(68.24)
	d. Employee benefits expense	3,910.55	4,033.19	3,551.38	12,040.75	10,822.88	14,681.81
	e. Depreciation and amortization expense	1,022.56	1,004.00	1,011.00	3,003.56	3,002.00	3,759.99
	f. Exchange Fluctuation Transactional (Gain)/Loss	66.70	86.78	41.70	272.20	18.22	58.16
	g. Other Expenses	7,222.56	7,556.39	7,578.87	22,099.58	21,579.68	28,633.60
	Total Expenses	22,397.62	24,314.30	22,502.73	71,156.90	68,188.00	90,233.71
3	Profit from Operations before Other Income and Finance Cost (1-2)	5,437.79	4,363.80	3,844.11	13,777.46	12,444.89	15,908.41
4	Other Income	1,290.99	2,651.63	195.92	4,372.33	890.40	1,040.88
5	Profit from ordinary activities before Finance Cost (3+4)	6,728.78	7,015.43	4,040.03	18,149.79	13,335.29	16,949.29
6	Finance Cost	259.83	308.41	284.71	739.27	642.68	665.01
7	Profit from ordinary activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	6,468.95	6,707.02	3,755.32	17,410.52	12,692.61	16,284.28
8	Exchange Fluctuation Translation Gain / (Loss)	35.27	(478.49)	(241.28)	(44.58)	(654.80)	(373.86)
9	Profit from ordinary activities before Tax (7+8)	6,504.22	6,228.53	3,514.04	17,365.94	12,037.81	15,910.42
10	Tax expense	1,515.00	1,330.00	1,097.26	4,050.00	3,253.20	4,552.17
11	Net Profit from ordinary activities after Tax (9-10)	4,989.22	4,898.53	2,416.78	13,315.94	8,784.61	11,358.25
12	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,696.40	1,696.40	1,696.16	1,696.40	1,696.16	1,696.16
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	99,934.99
14	Earnings per share (EPS) (of Rs. 2/- each) (not annualised)						
	(1) Basic	5.88	5.78	2.85	15.70	10.36	13.40
	(2) Diluted	5.88	5.78	2.85	15.70	10.36	13.39
	See accompanying notes to the Financial Results						

NOTES

- The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on February 3, 2016.
- The statutory auditors have carried out limited review of the above financial results for the quarter ended on December 31, 2015.
- The other income includes Rs. 12.57 crores on account of profit / dividend on investments.
- The company is engaged in a single segment of activity viz. Pharmaceuticals.
- The previous quarter's/period's figures have been re-grouped/re-stated, wherever necessary.

Place : Mumbai
Date : February 3, 2016



For J.B. Chemicals & Pharmaceuticals Ltd.

J.B. Mody
J.B. Mody
Chairman & Managing Director